DIA.WAR Diagnostyka S.A.
- Market cap
- PLN 5.06B
- P/E
- 19.8x
- P/B
- 9.95x
- ROE
- 54.9%
- Dividend yield
- 2.21%
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DIA.WAR undervalued?
Graham numberDIA.WAR trades 195.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diagnostyka S.A. fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (54.9%), above 20%.
ROA 1/1
Return on assets (12.5%) is above the industry median (5.5%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (12.7%) is below the industry median (33.8%).
Revenue Growth 2/2
Revenue grew 18.9% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (144.2%), above 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 6.7x against interest expense, well covered.
PE vs Market 0/1
PE (19.8x) is above the market median (11.6x).
PE vs Industry 0/1
PE (19.8x) is above the industry median (11.6x).
PBV 0/1
Price to book (10.0x) is above the industry median (2.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 196.6, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.2%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 44.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Diagnostyka S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diagnostyka S.A.
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides se…
Full company profileDiagnostyka S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Diagnostyka S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.84B | 1.44B | 1.59B | 1.95B | 2.41B | 2.71B |
| Gross Profit | 1.30B | 936M | 1.03B | 1.53B | 1.91B | 2.13B |
| Operating Income | 688M | 252M | 233M | 337M | 384M | 438M |
| EBITDA | - | 381M | 375M | 510M | 588M | 672M |
| Net Income | 558M | 167M | 123M | 223M | 252M | 280M |
| EPS | 17 | 4.96 | 3.66 | 6.62 | 7.45 | 8.29 |
| Balance Sheet | ||||||
| Total Assets | 1.26B | 1.20B | 1.40B | 1.72B | 2.07B | 2.23B |
| Total Liabilities | 819M | 878M | 1.06B | 1.28B | 1.52B | 1.70B |
| Shareholders' Equity | 438M | 313M | 325M | 419M | 528M | 510M |
| Cash & Short-term Investments | 164M | 91.0M | 94.9M | 40.5M | 18.4M | 17.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 739M | 284M | 336M | 415M | 552M | 526M |
| Capital Expenditure | 132M | 89.4M | 81.3M | 133M | 205M | 134M |
| Free Cash Flow | 607M | 195M | 255M | 283M | 347M | 392M |
| Ratios | ||||||
| ROE | 127.5% | 53.6% | 38.0% | 53.3% | 47.6% | 54.9% |
| ROA | 44.2% | 14.0% | 8.8% | 13.0% | 12.2% | 12.5% |
| Net Profit Margin | 30.3% | 11.7% | 7.8% | 11.5% | 10.4% | 10.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Diagnostyka S.A. dividends
- Dividend yield
- 2.21%
- Forward dividend
- 4.40 PLN
- Payout ratio
- 44.4%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | PLN 112M | 3.31 | 44.4% |
| 2024 | PLN 106M | 3.13 | 47.3% |
| 2023 | PLN 112M | 3.32 | 90.8% |
| 2022 | PLN 294M | 8.72 | 175.8% |
| 2021 | PLN 413M | 12 | 74.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Diagnostyka S.A.
- Insiders 47.20%
- Institutions 17.16%
- Public & others 35.64%
- Shares outstanding 33.8M
- Free float 16.4M
Diagnostyka S.A. company profile
- Company name
- Diagnostyka S.A.
- Ticker
- DIA.WAR
- ISIN
- PLDGNST00012
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 8,645
- Fiscal year end
- December
- Address
- Ul. Prof. Michala Zyczkowskiego 16, Kraków, Poland, 31-864
- Phone
- 48 12 295 0100
- Website
- diag.pl
About Diagnostyka S.A.
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides services to individual clients, and public and private entities. Diagnostyka S.A. was founded in 1998 and is headquartered in Kraków, Poland.
Diagnostyka S.A. management
4- Mr. Jakub SwadzbaCo-Founder, CEO & President of the Management Board
- Mr. Jaromir PelczarskiVice-President of the Management Board & Chief Transformation Officer
- Ms. Marta Rogalska-KupiecVice-President of the Management Board & Chief Operating Officer
- Mr. Dariusz ZowczakChief Sales Officer & Vice-President of the Management Board